What Is Eylea HD, and Why Does It Matter? Eylea HD (aflibercept) is an injectable medicine used to treat certain eye conditions that can lead to vision loss. It works by blocking a protein called VEGF ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

An FDA target action date of August 19, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application ...

STOCKHOLM — A real-world analysis of retrospective data showed that administering more anti-VEGF injections over a 5-year time span to treat macular edema secondary to retinal vein occlusion (RVO) was ...

CRVO occurs when blood can no longer travel through the main blood vessel that brings blood to the back of the eye. This can cause swelling, and it may lead to vision loss. The retina is a layer of ...

Roche RHHBY announced positive top-line long-term results from two global late-stage studies on the ophthalmology drug Vabysmo (faricimab). The phase III BALATON and COMINO studies are evaluating the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...

Each terminal choroidal arteriole supplies an independent lobule (segment) of the lamina choriocapillaris. Occlusion of these terminal arterioles produces a corresponding perfusion defect, and its ...